Compare EA & A Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EA | A |
|---|---|---|
| Founded | 1982 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Laboratory Analytical Instruments |
| Sector | Technology | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.8B | 38.0B |
| IPO Year | 2007 | 1999 |
| Metric | EA | A |
|---|---|---|
| Price | $209.84 | $145.97 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 18 | 15 |
| Target Price | ★ $191.33 | $161.47 |
| AVG Volume (30 Days) | ★ 4.9M | 1.7M |
| Earning Date | 05-05-2026 | 05-27-2026 |
| Dividend Yield | 0.38% | ★ 0.92% |
| EPS Growth | N/A | ★ 3.16 |
| EPS | 1.56 | ★ 2.27 |
| Revenue | ★ $7,531,000,000.00 | $4,472,000,000.00 |
| Revenue This Year | $10.69 | $8.45 |
| Revenue Next Year | $3.89 | $6.13 |
| P/E Ratio | $134.51 | ★ $62.27 |
| Revenue Growth | 0.91 | ★ 6.43 |
| 52 Week Low | $164.50 | $108.35 |
| 52 Week High | $210.20 | $160.27 |
| Indicator | EA | A |
|---|---|---|
| Relative Strength Index (RSI) | 71.88 | 62.69 |
| Support Level | $201.93 | $141.22 |
| Resistance Level | N/A | $151.38 |
| Average True Range (ATR) | 0.56 | 3.68 |
| MACD | -0.01 | 0.19 |
| Stochastic Oscillator | 88.12 | 93.86 |
Electronic Arts is one of the largest global developers and publishers of video games. Its most important franchises are the Madden NFL and FC soccer games, which it releases annually. In 2024, it also relaunched its American college football game. Other major franchises include Apex Legends, Battlefield, and The Sims. Typically, about three-quarters of the firm's sales are from in-game spending, with the remainder coming from initial game sales.
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and diagnostics, cross lab operations consisting of consumables and services, and applied end markets. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest country concentrations.